Aurobindo Pharma (AUROPHARMA)
STALWARTFairStock Score: 63/100 — STEADY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,435.9 |
| Market Cap | ₹70,881.03 Cr |
| P/E Ratio | 20.07 |
| ROCE | 14.18% |
| ROE | 10.68% |
| Dividend Yield | 0.33% |
| Profit Growth | -0.12% |
| Debt/Equity | 0.22 |
| Sales Growth | 7.31% |
| Free Cash Flow | ₹2,05,900 Cr |
| Promoter Holding | 51.82% |
| 52-Week Range | ₹1,016.1 — ₹1,550 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹562.21 |
Aurobindo Pharma trades with a P/E ratio of 20.07, ROCE of 14.18%, ROE of 10.68%, profit growth of -0.12%, debt-to-equity of 0.22. The FairStock Score of 63/100 suggests mixed fundamentals — some metrics look solid while others need improvement.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer